AB0311 ANALYSIS OF THE MALIGNANCY-RELATED SAFETY OF ABATACEPT FOR RHEUMATOID ARTHRITIS IN CLINICAL PRACTICE

Background In 2019, a study based on post-marketing surveillance data in Japan reported that ABT was as effective and safe elderly patients with rheumatoid arthritis (RA) non-elderly [1] . However, there were inconsistent reports the impact of malignancies which are more common strongly related to prognosis [2-4] , still unanswered questions. Objectives To evaluate incidence malignancy efficacy safety previous RA using our clinical practice. addition, explore predictive risk factors developing or relapsing during use. Methods Patients who received for at department from October 2010 May 2022 included study. Patient background, prior starting ABT, disease activity up 60 months, continuation rates safety, including onset recurrence use, retrospectively collected electronic medical records. The divided into two groups according absence presence (No malignancy: NP group, PM group), parameters compared between groups. Results A total 276 included, 61 had when ABT. age significantly higher group (72.5 ± 10.6 vs. 68.5 13.0years-old, p = 0.025), rate methotrexate use lower (29.5 51.2%, 0.0028), although no significant differences other patient backgrounds (Table 1). improved three months after both groups, DAS28-CRP remission maintained that. There difference after. 1-year 5-year (86.3 86.6%, 70.5 65.7%, respectively, Figure 14 cases occurrence progression observation period. 1324.6 per 100,000 person-years, Japanese national survey similar age. Despite older population 5-years Binomial logistic analysis performed such age, duration, history malignancy, concomitant medications, found be associated development relapse this Conclusion practice, without malignancy. References Mod Rheumatol 2019 Sep; 29(5): 747-755. [2] Rheumatology 2019; 58: 683–91. [3] Arthritis Res Ther 21: 228. [4] 2020; 59: 2360–7. Table 1. background start (n 215) (n=61) ρ Female (n, %) 182/215 (84.7) 49/61 (80.3) 0.42 Age (y.o.) 13.0 72.6 0.025 Disease duration (year) 9.7 9.5 11.8 10.3 0.13 Body weight (kg) 53.4 12.0 52.2 9.6 0.49 RF seropositivity 181/214 (84.6) 52/61 (85.2) 0.94 Anti-CCP Ab 152/184 (82.6) 47/52 (90.4) 0.25 Complications CTD 31/214 (14.5) 12/61 (19.7) 0.33 Interstitial pneumoniae 47/215 (21.9) 9/61 (14.8) 0.30 b/tsDMARDs naïve 152/214 (71.0) 45/61 (73.8) 0.68 Concomitant drug MTX 110/215 (51.2) 18/61 (29.5) 0.0028 dose (mg/week) 10.4 2.7 9.9 2.2 0.43 PSL 60/213 (28.2) 20/61 (32.8) 0.48 (mg/day) 5.8 5.1 5.2 4.1 0.65 MMP-3 (ng/ml) 262.1 278.3 294.1 303.8 0.46 3.8 1.0 3.9 1.2 0.91 DAS28-ESR 5.3 1.1 1.4 0.86 CDAI 20.2 21.2 12.3 0.62 SDAI 22.4 12.9 23.6 13.2 0.61 Acknowledgements: NIL. Disclosure Interests Yosuke Kunishita Speakers bureau: AbbVie, Asahi Kasei Pharma, Astellas AstraZeneca, Ayumi Pharmaceuticals, Boehringer Ingelheim Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, Janssen Kyowa Kirin, Sanofi, UCB, Paid instructor for: Kayo Harita: None declared, Chikara Honda: Yuji Uzawa: Masaki Mitsuhashi: Soichi Ohta: Toshihisa Igarashi: Shouhei Nagaoka: declared.